seekingalpha.com
SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
SOPHiA GENETICS S.A.SOPHNASDAQ
Loading
Latest News
Loading news...
prnewswire.com
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results
BOSTON and ROLLE, Switzerland, March 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial Results Revenue was $21.7 million, up 22% year-over-year Gross margin was 67.7% on a reported basis and 73.9% on an adjusted basis, compared to 68.2% reported and 74.2% adjusted in the prior year period IFRS net loss was $19.2 million, an increase of 27% year-over-year; Adjusted EBITDA loss was $9.9 million, an increase of 9% year-over-year Full Year 2025 Financial Results Revenue was $77.3 million, up 19% year-over-year Gross margin was 67.4% on a reported basis and 74.2% on an adjusted basis, compared to 67.4% reported and 72.8% adjusted in the prior year period IFRS net loss was $79.0 million, an increase of 26% year-over-year; Adjusted EBITDA loss was $41.5 million, an increase of 3% year-over-year "We finished 2025 strong, with Q4 revenue growing 22% and full-year revenue increasing 19% year-over-year, as our growth momentum continues to accelerate," said Jurgi Camblong, Chief Executive Officer and co-founder of SOPHiA GENETICS.
prnewswire.com
SOPHiA GENETICS to Present at the 46th Annual TD Cowen Health Care Conference
BOSTON and ROLLE, Switzerland, Feb. 25, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced that leadership will present at TD Cowen's 46th Annual Health Care Conference in Boston. Jurgi Camblong, Chief Executive Officer and co-founder of SOPHiA GENETICS, and Ross Muken, President of SOPHiA GENETICS, will participate in a fireside chat on Wednesday, March 4, 2026, at 10:30 am EST / 4:30 pm CET.
prnewswire.com
SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2025 on March 3, 2026
BOSTON and ROLLE, Switzerland, Feb. 17, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the fourth quarter and full year 2025 before U.S. markets open on Tuesday, March 3, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.
prnewswire.com
SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems
BOSTON and ROLLE, Switzerland, Feb. 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest U.S. healthcare systems to its network. The two new institutions, which collectively analyze millions of genetic samples annually, include one of the leading nonprofit, multi-region integrated healthcare systems in the U.S. and a top 10 U.S. health system laboratory.
defenseworld.net
Comparing SOPHiA GENETICS (NASDAQ:SOPH) & Precipio (NASDAQ:PRPO)
Precipio (NASDAQ: PRPO - Get Free Report) and SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends. Institutional and Insider Ownership 10.5% of Precipio shares
defenseworld.net
SOPHiA GENETICS (NASDAQ:SOPH) versus Pulmonx (NASDAQ:LUNG) Critical Comparison
SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) and Pulmonx (NASDAQ: LUNG - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership. Risk and Volatility SOPHiA GENETICS has a beta
defenseworld.net
1,409,160 Shares in SOPHiA GENETICS SA $SOPH Bought by Alta Wealth Advisors LLC
Alta Wealth Advisors LLC purchased a new stake in SOPHiA GENETICS SA (NASDAQ: SOPH) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,409,160 shares of the company's stock, valued at approximately $6,708,000. SOPHiA GENETICS accounts for about 2.4% of
prnewswire.com
SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan
The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and promotes Ross Muken to CEO BOSTON and ROLLE, Switzerland, Jan. 12, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today provided preliminary unaudited financial results for the fourth quarter and full year 2025, initiated its financial outlook for 2026, and announced an executive transition plan, including the promotion of Ross Muken to Chief Executive Officer (CEO), effective July 1, 2026, and the transition of co-Founder Jurgi Camblong to Executive Chairman. Fourth Quarter 2025 Preliminary Unaudited Financial Results Revenue of at least $21 million, representing an increase of approximately 20% year-over-year Performed over 105,000 analyses on SOPHiA DDM™ in the fourth quarter, representing 16% year-over-year growth Full Year 2025 Preliminary Unaudited Financial Results Revenue of approximately $77 million, representing an increase of approximately 18% year-over-year Performed over 391,000 analyses on SOPHiA DDM™ in 2025, a new company record "2025 was a tremendous year for SOPHiA GENETICS as we reaccelerated revenue growth and materially exceeded our new business bookings target, setting the stage for robust future growth," said Jurgi Camblong, Chief Executive Officer of SOPHiA GENETICS.
defenseworld.net
Analyzing MSP Recovery (NASDAQ:MSPR) & SOPHiA GENETICS (NASDAQ:SOPH)
SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) and MSP Recovery (NASDAQ: MSPR - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations. Valuation and Earnings This table compares SOPHiA
prnewswire.com
SOPHiA GENETICS and MD Anderson Announce Strategic Collaboration to Accelerate AI-Driven Precision Oncology
BOSTON and HOUSTON, Jan. 7, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice. As part of the collaboration, MD Anderson and SOPHiA GENETICS are launching a series of research and development programs and co-developing an advanced next-generation sequencing oncology test.
defenseworld.net
SOPHiA GENETICS (NASDAQ:SOPH) Trading 2.8% Higher – What’s Next?
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH - Get Free Report) shot up 2.8% during mid-day trading on Friday. The company traded as high as $4.75 and last traded at $4.73. 45,371 shares traded hands during trading, a decline of 38% from the average session volume of 73,308 shares. The stock had previously closed at
defenseworld.net
Comparing SOPHiA GENETICS (NASDAQ:SOPH) and Azenta (NASDAQ:AZTA)
Azenta (NASDAQ: AZTA - Get Free Report) and SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation. Volatility and Risk Azenta has a beta of
prnewswire.com
SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine
BOSTON , Nov. 11, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on Complete Genomics' DNBSEQ-T1+ sequencing platform. The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tumor applications to customers globally.
prnewswire.com
SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine
BOSTON and SAN DIEGO , Nov. 11, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology company transforming the pace and accessibility of scientific discovery, today announced at the Association for Molecular Pathology (AMP) Annual Meeting a partnership that unites sequencing and AI analytics to streamline genomic workflows and accelerate the research supporting precision medicine. This collaboration integrates SOPHiA GENETICS' AI-powered analytics platform, SOPHiA DDM™, with Element's AVITI24™ 5D multiomic and AVITI™ sequencing systems to deliver a seamless, end-to-end workflow for next-generation sequencing (NGS).
seekingalpha.com
SOPHiA GENETICS SA (SOPH) Q3 2025 Earnings Call Transcript
SOPHiA GENETICS SA ( SOPH ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Kellen Sanger - Head of Strategy and Investor Relations Jurgi Camblong - Co-Founder, CEO & Director Ross Muken - President George Cardoza - Executive VP & CFO Conference Call Participants William Bonello - Craig-Hallum Capital Group LLC, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Mark Massaro - BTIG, LLC, Research Division Kyle Boucher - TD Cowen, Research Division Presentation Operator Good morning. My name is Kelsey, and I'll be your conference operator today.
prnewswire.com
SOPHiA GENETICS Reports Third Quarter 2025 Results and Increases 2025 Revenue Guidance
BOSTON and ROLLE, Switzerland , Nov. 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Revenue was $19.5 million, up 23% year-over-year Gross margin was 66.3% on a reported basis and 73.1% on an adjusted basis, compared to 67.2% reported and 73.1% adjusted in the prior year period Net IFRS loss was $20.0 million, up 9% year-over-year; Adjusted EBITDA loss was $10.2 million, up 8% year-over-year; Excluding the impact of elevated Swiss social charges on equity-based compensation following share price appreciation, adjusted EBITDA loss would have been $8.8 million, representing a 13% year-over-year improvement 2025 Financial Outlook Full year revenue is now expected to be in the range of $75 to $77 million, representing year-over-year growth of 15% to 18%.
prnewswire.com
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2025 on November 4, 2025
BOSTON and ROLLE, Switzerland , Oct. 21, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the third quarter 2025 before U.S. markets open on Tuesday, November 4, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.
prnewswire.com
A.D.A.M. Innovations and SOPHiA GENETICS partner to advance liquid biopsy testing and companion diagnostics for precision oncology in Japan
ROLLE, Switzerland and TOKYO , Oct. 16, 2025 /PRNewswire/ -- A.D.A.M. Innovations, Japan's leading private genetic testing company, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company pioneering data-driven medicine, today announced at ESMO a strategic agreement to bring cutting-edge liquid biopsy genomic testing to the Japanese population.
prnewswire.com
SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology
BOSTON and ROLLE, Switzerland , Oct. 16, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in AI-driven precision medicine, today announced the launch of SOPHiA DDM™ Digital Twins, a breakthrough research technology that creates dynamic, virtual representations of individual patients to simulate potential outcomes and help oncologists make better treatment decisions. SOPHiA DDM™ Digital Twins uses each patient's unique clinical, biological, imaging, and genomic data to generate a computational replica of the patient and their individual disease.